Kudos Launches Showcase to Increase the Public’s Understanding of the Future Role of AI

As we use artificial intelligence (AI) in more parts of everyday life, more people are questioning how it works, how it is applied and if they should trust it. To provide the public with these answers, some of the most influential academic publishers have partnered together to launch the Artificial Intelligence Knowledge Cooperative, collated by, Kudos, the platform for showcasing science.

The Showcase will provide better access to credible research about AI and its usage in easy-to-understand summaries.

According to a 2022 report by Tortoise Intelligence, worldwide investment into AI companies has increased by 115 per cent since 2020, marking the largest year-on-year growth in AI investment for at least two decades. Despite its integration into our lives, some businesses and members of the public are unsure about the impact of AI.

Kudos developed the AI knowledge cooperative, alongside publishers such as the Association for Computing Machinery, AIP Publishing, ASTM International and IOP Publishing, to provide media, industry, policy makers and the public with credible information that will help them understand the current and future role of AI. Each piece of research has been summarised into easy-to-understand language by expert writers to ensure everyone can access this research.

“From chatbots to self-driving vehicles, we are beginning to get used to AI in everyday life,” explained Charlie Rapple, chief customer officer and co-founder of Kudos. “As AI becomes more widespread, the public only has increasing questions about the impact the technology will have on our way of life, number of jobs and level of human interaction.

“Many questions about AI are already being answered by research in the field, so researchers have a big role to play in educating the public about an increasingly powerful and pervasive technology. Commonly only research papers published in high tier journals will be read, so this platform acts to increase the amount of vital research being read by the public and influential researchers in the AI industry,” concluded Rapple.

The curated content will focus on several areas of AI, such as the impact of hyperintelligence, regulations and ethics around the use of AI, how AI can assist with disease prevention and artificial moral agents.

The initiative will help develop trust and understanding between the research community and the public. It will help decision makers make more informed decisions about technologies they invest in, encourage people to adopt AI in their own homes and reduce the fear or distrust that is occurring around the technology.

To explore the most influential and insightful AI research for yourself, visit the collection here.

SourceKudos

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”